OMNIOME APPOINTS ROBERT WICKE AS CHIEF EXECUTIVE OFFICER
Robert Wicke brings comprehensive leadership to innovative start-up
SAN DIEGO- November 20, 2020- Omniome, Inc., developer of a novel DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, today announces the appointment of Robert Wicke as Chief Executive Officer. He will immediately assume day-to-day leadership and join Omniome’s Board of Directors.
Robert brings over 30 years’ experience to the company, having held executive leadership roles and Board of Directors positions in life science and technology companies. Robert comes to Omniome from Halo Labs where he held the role of Chief Executive Officer. Previously, he held executive leadership roles at ForteBio, Pall Corporation, Molecular Devices and Axon Instruments where his teams launched revolutionary new platforms and demonstrated strong revenue growth with continuous product pipeline development. Robert has also orchestrated multiple successful acquisitions throughout his career.
“We are excited to welcome Robert to the Omniome team. His executive experience and demonstrated product launch success will lead us as we prepare for commercial launch of our groundbreaking sequencing platform,” said Ken Song, M.D., Executive Chairman of Omniome.
Robert Wicke, the new Chief Executive Officer of Omniome, commented: “I am very excited to join this team. Our fundamental Sequencing-By-Binding technology coupled with the wealth of talented people here at Omniome will uniquely position us to impact the Next Generation Sequencing space in areas that have not seen improvement for a long time. I am thrilled to help chart the future course for our success and deliver the most accurate sequencing technology in the world.”
OMNIOME APPOINTS RICHARD SHEN, PH.D AS CHIEF PRODUCT OFFICER
A recognized seasoned industry veteran, Richard brings extensive expertise in Next Generation Sequencing technology and system development
SAN DIEGO- September 29, 2020- Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, today announces the appointment of Richard Shen, Ph.D. as Chief Product Officer.
Richard brings over 25 years’ experience in the genomics space, having held senior leadership and Board of Directors positions in several molecular diagnostics and next generation sequencing companies. Richard spent 16 years at Illumina in a number of roles, including as Vice President, Oncology R&D and Vice President, Consumables Product Development, among others. Before Illumina, Richard led the High-Throughput Sequencing Facility at Myriad Genetics.
“We are excited to welcome Richard to the Omniome team. His deep experience in product development in the Next Generation Sequencing space will complement our team,” said Ken Song, M.D., Executive Chairman of Omniome. “Richard will have direct oversight of final product development and launch of our groundbreaking sequencing platform.”
Richard Shen, Ph.D., Chief Product Officer of Omniome, commented: “I am excited to join Omniome at such a key time in the Company’s development. With its cutting-edge technology and collective expertise, Omniome is uniquely positioned to make a significant impact in the Next Generation Sequencing space. I am thrilled to become part of the team and to contribute to Omniome’s success in delivering its best-in-class sequencing technology to the market.”
OMNIOME CLOSES $60 MILLION SERIES C FINANCING TO ADVANCE NOVEL GENOMIC SEQUENCING PLATFORM
Company Raises $145 Million in Eighteen Months to Complete Development and Early Commercialization of Breakthrough DNA Sequencing Platform
SAN DIEGO—January 9, 2020 – Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, today announced it has raised an additional $60 million with the completion of its Series C financing. The funding round was led by Madrone Capital Partners. Current investors include ARCH Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Sciences Ventures, Nan Fung Life Sciences and others. The company, which raised $60 million in financing in mid-2018, will utilize the new $60 million equity financing in addition to previous debt financing in order to accelerate late-stage product development and launch planning. “Our product development efforts are advancing rapidly and shifting towards delivering our first beta prototype instruments”, said Dave Mullarkey, President and CEO at Omniome. “We welcome Madrone and appreciate ongoing support from our current investors in executing on our plans.” The company will deploy portions of the financing proceeds to expand the company’s capabilities by hiring new team members across multiple disciplines, particularly in manufacturing, engineering, development, customer support and commercial. The company will continue to optimize its proprietary technology while accelerating instrument development and delivery of commercially-impactful sequencing platforms. “Omniome has made incredible progress over the past couple years maturing from an early product concept company to a late stage product development company”, said Ken Song, M.D., Omniome’s Executive Chairman. “The goal and vision have always been to develop a disruptive sequencing technology taking into account accuracy, speed, throughput, and cost. The team’s success in advancing product development across these dimensions has attracted considerable interest from top tier investors.”